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Successful implementation of low radiation dose CT lung cancer screening, depends on a 
number of well-researched factors that improve the balance between benefits and harms. One 
of the most important is the identification of individuals at high risk of developing and dying 
from lung cancer. There is debate about the threshold that defines high enough risk and the 
method for estimating risk, with several multivariable risk models available. The findings 
from the PanCan study shed further light on this topic.  
 
Although there is still debate about whether LDCT lung cancer screening should be offered at 
all, most protagonists agree that screening should only be offered to people with a high risk 
of lung cancer, where benefits are likely to outweigh harms and the number needed to screen 
to prevent a death supports cost effectiveness.  Since the publication of the National Lung 
Cancer Screening Trial (NLST ) [1] which demonstrated that lung cancer screening can 
reduce mortality by 20% in high risk smokers, it has been shown that the number needed to 
screen was lowest in the 40% of recruits who were at highest risk [2]. Accordingly, cost 
effectiveness was also highest in the high-risk groups [3]. The US Preventive Forces Task 
Force recommended that lung cancer screening was based on age –extended NLST selection 
criteria [4] (55 – 80 years of age, minimum 30 pack years and quit smoking within the 
previous 15 years).  
 
A number of publications have shown that lung cancer risk prediction models out-perform 
these criteria, both increasing the sensitivity for identifying those who develop lung cancer 
and reducing the number screened who do not develop cancer. One of the first risk models 
used in a lung cancer CT screening project setting, was the PanCan risk model [5], which 
predates the PLCOm2012 [6].  PanCan was utilised in the Pan-Canadian early detection study, 
started in 2004, undertaken in eight centres in Canada and the recruited participants were 
offered three consecutive scans.  PanCan was a cohort study and the patients’ were not 
recruited at random but through advertising campaigns. PanCan selected the participants on 
the basis of their model predicted risk (2% over 6 years) and 2537 patients were recruited and 
received a baseline screen.  
 
Since this study was started, 14 years ago, radiological protocols for CT screen detected 
nodules have been improved based on accumulating evidence, including that from the 
PanCan study [7]. PanCan defined an abnormal CT as the presence of any non-calcified or 
non-perifissural pulmonary nodule of at least 1 mm maximum diameter [5]. The NLST trial 
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used 4mm maximum diameter as their threshold, whilst the NELSON and UKLS utilised 
volumetric analysis [8] [9]. The current volumetric management of screen-detected 
pulmonary nodules is outlined in the recent European Union Position Statement (EUPS) [10].    
 
Based on modelling, the PanCan investigators calculated that the median risk in the 
population screened was 3.3% but found that the incidence of lung cancer over 5.5 years was 
double that (6.5%, 164/2537) which is also significantly higher than that reported by the 
NLST, with a 4% incidence. The PanCan and PLCOm2012 risk models demonstrated, at best, 
modest overall prediction with ROC AUC‡ of 0·629 (95% CI 0·588-0·667) and 0·614 (95% 
CI 0·570-0·658) respectively, (data only shown in the supplementary PanCan publication[5]). 
 
PanCan has provided convincing evidence of a non RCT study utilising a risk prediction 
model with 5.5 years of follow-up. PLCOm2012 has been shown to outperform the NLST 
entry criteria, which are similar to the USPSTF criteria (apart from age criteria 55-80y) upon 
which reimbursement is based in North America.  However, the disparity in the PanCan 
baseline detection 5.1%  rate of lung cancer (129 individuals with cancer, of 2537 screened), 
with estimated average risk and the modest AUC, show that there is room for improvement, 
something that has also been demonstrated in modelling studies [11]. UKLS, the only 
published RCT to use a risk prediction model to select subjects utilised a 5% risk over 5 years 
[9], yet the baseline detection rate was lower at 2.1%, and much more in keeping with what 
would be expected after a single screen. UKLS has not yet published the 5 year cumulative 
cancer incidence but this potentially could now be measured to confirm the predictive 
accuracy of the LLPv2 model. 
 
There have only been two major lung cancer screening projects undertaken in North America 
since the publication of the NLST.  The PanCan trial can be compared in a number of ways 
with the CT lung cancer demonstration project undertaken by the US Veterans Affairs (VA) 
health system lung cancer screening programme, which started in 2015[12]. The VA lung 
cancer screening project utilised the USPSTF recommendations, surprisingly, this project had 
a very high rate of false positives with 56% of the 2184 subjects screened, (i.e. nodules 
requiring follow up with repeat scans or invasive procedures), compared with the NLST 
26.3% [1, 12] . Lung cancer was detected in 1.5% and the low rate of detection of early stage 
disease is disappointing.  Indeed, this is in sharp contrast to many other studies, including the 
most recent real-world demonstration  programmes in Manchester UK, which utilised the 
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PLCOm2012 risk prediction model [13] and the Liverpool Health Lung Project , utilising the 
LLPv2 risk model [14], to select high risk patients . This has naturally raised the question if a 
more targeted approach had been used, would the VA project have been more successful; 
which has been addressed by Caverly and colleagues [15].  Firstly, they used previously 
published findings from NLST that the 20% relative risk reduction in lung cancer mortality 
did not change according to baseline risk. Thus, they calculated absolute risk reduction and 
utilised the Bach risk model to calculate the annual baseline mortality risk and analysed the 
data by risk quintiles. It’s of note that Caverly et al. used the Bach lung cancer risk model 
[16], which is considered one of the simplest models but has been shown to perform 
similarly, when compared to the more complex models [11] . The Bach model only utilises 
smoking and age.  Unsurprisingly, the patients in the higher quintiles in the VA project had a 
significantly larger number of cancers (number of lung cancers diagnosed / 1000 screened; 
quintile 1, 4.8 v 29.7 in quintile 5). The number required to screen / lung cancer death 
prevented: 6903 in quintile 1 compared with 687 in quintile 5. However, the false positive 
rate did not change greatly across the quintiles.  
 
Both the PanCan and the re-analysed VA study utilising the Bach risk model reflect the use 
of participant selection and nodule management protocols, the latter is now considered 
outdated, partly as a result of data generated by the PanCan study and the models are clearly 
suboptimal. Given the marked influence of accurate risk prediction on the cost effectiveness 
of CT screening, itself a balance of resource utilisation and minimisation of harms, it is 
essential that more work is devoted to the development on models and the method of 
participant recruitment in the real world. Selection of a high-risk group using PLCOm2012 has 
been successful in Manchester, but it is unclear how much the model influenced the excellent 
results, as the vast majority of patients were clearly at high risk and a model would not have 
been required to select them.  Indeed, models are only really useful in determining eligibility 
where it is close to the agreed risk threshold. Developing models specifically designed to 
address this subgroup may be a future approach. The EUPS on lung cancer screening [10] 
demonstrates the dramatic leap in our understanding around patient selection and nodule 
management, thus resetting the balance between harm and benefit in the patient favour as, 
well as reducing false positive rates. The EUPS recommends that either of the two risk  
models PLCOm2012 and the LLPv2 could be utilised at this time, although refinement of 
models is important. Risk thresholds will be mainly dependent on the cost acceptable in each 
country (i.e. utilising the LLPv2 at 3% risk will increase the number of cancer identified but 
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will require a significantly larger number of patients to be screened  [17]).  This is clearly 
seen in the cost effectiveness studies undertaken in the PanCan, NLST and UKLS CT 
screening projects, CAN$20,724 per life gained [18], the NLST with US$81,000 [3] and the 
UKLS £6,325 per life-year gained [9]. 
 
Countries implementing future lung cancer screening programmes, will have to decide on the 
most appropriate risk assessment model and threshold, to select their high-risk individuals, 
based on their national health funding model (insurance or public purse), the level of 
acceptable cost effectiveness, together with the social and ethical attitudes to screening, based 
on ‘personal risk factors’. To date we have little information on the latter. 
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